1. Home
  2. SMTI vs DHF Comparison

SMTI vs DHF Comparison

Compare SMTI & DHF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sanara MedTech Inc.

SMTI

Sanara MedTech Inc.

N/A

Current Price

$21.50

Market Cap

208.2M

Sector

Health Care

ML Signal

N/A

Logo BNY Mellon High Yield Strategies Fund

DHF

BNY Mellon High Yield Strategies Fund

HOLD

Current Price

$2.40

Market Cap

176.2M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
SMTI
DHF
Founded
1982
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Finance Companies
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
208.2M
176.2M
IPO Year
2008
1998

Fundamental Metrics

Financial Performance
Metric
SMTI
DHF
Price
$21.50
$2.40
Analyst Decision
Strong Buy
Analyst Count
2
0
Target Price
$34.00
N/A
AVG Volume (30 Days)
36.6K
178.9K
Earning Date
05-12-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.05
N/A
Revenue
$15,586,976.00
N/A
Revenue This Year
$17.31
N/A
Revenue Next Year
$12.48
N/A
P/E Ratio
$459.80
N/A
Revenue Growth
32.47
N/A
52 Week Low
$16.05
$2.33
52 Week High
$35.70
$2.63

Technical Indicators

Market Signals
Indicator
SMTI
DHF
Relative Strength Index (RSI) 50.84 42.58
Support Level $20.52 $2.38
Resistance Level $24.17 $2.47
Average True Range (ATR) 1.14 0.02
MACD -0.15 -0.00
Stochastic Oscillator 28.16 0.00

Price Performance

Historical Comparison
SMTI
DHF

About SMTI Sanara MedTech Inc.

Sanara MedTech Inc is a medical technology company focused on developing and commercializing technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market. It markets and sells soft tissue repair and bone fusion products for use in operating rooms and sterile environments. Its soft tissue repair products include CellerateRX Surgical Powder, a hydrolyzed collagen used in management of surgical wounds, and BIASURGE Surgical Solution, a sterile no-rinse solution for wound irrigation, while its bone fusion products include BiFORM Bioactive Moldable Matrix, an osteoconductive implant that supports bone growth, and ALLOCYTE Plus Viable Bone Matrix, a human allograft cellular bone matrix containing bone-derived progenitor cells and conformable bone fibers.

About DHF BNY Mellon High Yield Strategies Fund

BNY Mellon High Yield Strategies Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to seek high current income and its secondary objective is capital appreciation. The fund invests predominantly in fixed-income securities of below-investment-grade credit quality.

Share on Social Networks: